Overview

Safety and Efficacy Study of DuoTrav APS Versus DuoTrav

Status:
Withdrawn
Trial end date:
2009-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to demonstrate that the IOP-lowering efficacy of DuoTrav APS, dosed once-daily in the morning, is non-inferior to that of DuoTrav, dosed once-daily in the morning.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Alcon Research
Treatments:
Cloprostenol
Timolol
Criteria
Inclusion Criteria:

- Patients with open-angle glaucoma or ocular hypertension who would benefit from a
fixed combination medication, in the opinion of the investigator and who are currently
on a stable treatment of IOP-lowering medication

Exclusion Criteria:

- VA not worse than 0.60

- additional clinically relevant ocular or systemic conditions may be excluded